For pituitary tumors, positron emission tomography (PET) with 11C-methonine (MET) has been reported as feasible to facilitate diagnosis. MET is well-known to accumulate in the normal pituitary glands, but almost no studies have examined the degree of MET accumulation in the normal pituitary gland.
Purpose
To investigate accumulation of MET in normal pituitary gland on PET/CT.
Material and Methods
Among patients who underwent PET/CT using MET over the past 7 years, 77 patients who fulfilled our criteria for normal pituitary glands were retrospectively selected. Maximum standardized uptake value (SUVmax) for the pituitary gland was measured.
Results
SUVmax of MET in the pituitary gland was in the range of 0.9–6.6 (mean ± standard deviation = 2.60 ± 1.04). A negative correlation between SUVmax and patient age (y = −0.032 × + 4.29, n = 77, r = 0.55) was found by linear regression analysis. SUVmax of the pituitary gland did not differ significantly between women and men.
Conclusion
MET shows strong accumulation in normal pituitary gland. PET/CT would thus be feasible to differentiate between normal and abnormal pituitary glands.
JacobsAHThomasAKrachtLW, et al.18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med2005; 46: 1948–1958.
2.
KatoTShinodaJOkaN, et al.Analysis of 11C-methionine uptake in low-grade gliomas and correlation with proliferative activity. Am J Neuroradiol2008; 29: 1867–1871.
3.
OkitaYKinoshitaMGotoT, et al.11C-methionine uptake correlates with tumor cell density rather than with microvessel density in gliomas: A stereotactic image-histology comparison. Neuroimage2010; 49: 2977–2982.
4.
GlaudemansAWJMEntingRHHeestersMAAH, et al.Value of 11C-methionine PET in imaging brain tumours and metastases. Eur J Med Mol Imaging2013; 40: 615–635.
5.
BergstromMMuhrCLundbergO, et al.PET as a tool in the clinical evaluation of pituitary adenomas. J Nucl Med1991; 32: 610–615.
6.
MatsBCarinMSuhkwinderJ, et al.Differentiation of pituitary adenoma and meningioma: visualization with positron emission tomography and [11C]-L-deprenyl. Neurosurgery1992; 30: 855–861.
7.
TangBNTLevivierMHeureuxM, et al.11C-methionine PET for the diagnosis and management of recurrent pituitary adenomas. Eur J Nucl Med Mol Imaging2006; 33: 169–178.
8.
MuhrC. Positron emission tomography in acromegaly and other pituitary adenoma patients. Neuroendocrinology2006; 83: 205–210.
9.
Rodriguez-BarceloSGutierrez-CardoADominguez-PaezM, et al.Clinical usefulness of coregistered 11C-methionine positron emission tomography/3-T magnetic resonance imaging at the follow-up acromegaly. World Neurosurg2014; 82: 468–473.
10.
KoulouriOSteuweAGillettD, et al.A role for 11C-methionine PET imaging in ACTH-dependent Cusing’s syndrome. Euro J Endocrinol2015; 173: M107–M120.
11.
FengZHeDMaoZ, et al.Utility of 11C-methionine and 18F-FDG PET/CT in patients with functioning pituitary adenomas. Clin Nucl Med2016; 41: e130–e134.
12.
De SouzaBBrunettiAFulhamMJ, et al.Pituitary microadenomas: A PET study. Radiology1990; 177: 39–44.
13.
AlzahraniASFarhatRAl-ArifiA, et al.The diagnostic value of fused positron emission tomography/computed tomography in the localization of adrenocorticotropin-secreting pituitary adenoma in Cushing’s disease. Pituitary2009; 12: 309–314.
14.
JeongSYLeeSWLeeHJ, et al.Incidental pituitary uptake on whole-body 18F-FDG PET/CT: a multicenter study. Eur J Nucl Med Imaging2010; 37: 334–2343.
15.
BergstromMMuhrCEricsonK, et al.The normal pituitary examined with positron emission tomography and (methyl-11C)-L-methionine and (methyl-11C)-D-methionine. Neuroradiol1987; 29: 221–225.
16.
TomuraNItoYMatsuokaH, et al.PET findings of intramedullary tumors of the spinal cord using [18F] FDG and [11C] methionine. Am J Neuroradiol2013; 34: 1278–1283.
17.
RomanowskiCAJLeslieDFThurfjellL, et al.Construction of a standard reference for PET studies of methionine accumulation using a computerized brain atlas. Neuroradiology1997; 39: 389–393.
18.
CoopeDJCizekJEggersC, et al.Evaluation of primary brain tumors using 11C-methionine PET with reference to a normal methionine uptake map. J Nucl Med2007; 48: 1971–1980.
19.
NagataTTsuyuguchiNUdaT, et al.Examination of 11C-methionine metabolism by the standardized uptake value in the normal brain of children. J Nucl Med2011; 52: 201–205.
20.
FrancavillaTLMiletichRSDeMicheleD, et al.Positron emission tomography of pituitary macroadenomas: hormone production and effects of therapies. Neurosurgery1991; 28: 826–833.
21.
HyunSHChoiJYLeeKH, et al.Incidental focal 18F-FDG uptake in the pituitary gland: clinical significance and differential diagnostic criteria. J Nucl Med2011; 52: 547–550.
22.
LaserBSMerchantTEIndelicatoDJ, et al.Evaluation of children with craniopharyngioma using carbon-11 methionine PET prior to proton therapy. Neuro Oncol2013; 15: 506–510.
23.
OkochiYNihashiTFujiiM, et al.Clinical use of 11C-methionine and 18F-FDG-PET for germinoma in central nervous system. Ann Nucl Med2014; 28: 94–102.
24.
O’TuamaLAPhillipsPCSmithQR, et al.L-methionine uptake by human cerebral cortex; maturation from infancy to old age. J Nucl Med1991; 32: 16–22.
25.
UdaTTsuyuguchiNTerakawaY, et al.Evaluation of the accumulation of 11C-methionine with standardized uptake value in the normal brain. J Nucl Med2010; 51: 219–222.
26.
CummingsDEMerriamGR. Age-related changes in growth hormone secretion: should the somatopause be treated?Semin Reprod Endocrinol1999; 17: 311–325.
27.
VaninettiSBaccarelliARomoliR, et al.Effect of aging on serum gonadotrophin levels in healthy subjects and patients with nonfunctioning pituitary adenomas. Euro J Endocrinol2000; 142: 144–149.
28.
RoelfsemaFPijlHKeenanDM, et al.Prolactine secretion in healthy adults is determined by gender, age and body mass index. Plos One2012; 7(e31305): 1–10.
29.
PeetersR. Thyroid hormones and aging. Hormones2008; 7: 28–35.
30.
WangPSLoMJKauMM. Glucocorticoids and aging. J Formos Med Assoc1997; 96: 792–801.
31.
TsunodaAOkudaOSatoK. MR height of the pituitary gland as a function of age and sex: especially physiological hypertrophy in adolescence and in climacterium. Am J Neuroradiol1997; 18: 551–554.
32.
EricksonDEricksonBWatsonR, et al.3 Tesla magnetic resonance imaging with and without corticotrophin releasing hormone stimulation for the detection of micoadenomas in Cushing’s syndrome. Clin Endoclinol2010; 72: 793–799.
33.
TabarinALaurentFCatargiB, et al.Comparative evaluation of conventional and dynamic magnetic resonance imaging of the pituitary gland for the diagnosis of Cushing’s disease. Clin Endoclinol1998; 49: 293–300.
34.
KasaliwalRSankhetSSLilaAR, et al.Volume interporated 3D-spoiled gradient echo sequence is better than dynamic contrast spin echo sequence for MRI detection of corticotrophin secreting pituitary microadenomas. Clin Endoclinol2012; 78: 825–830.
35.
WindJJLonserRRNiemanLK, et al.The lateralization accuracy of inferior petrosal sinus sampling in 501 patients with Cushing’s disease. J Clin Endocrinol Metab2013; 98: 2285–2293.
36.
HarrisSMDavisJCSnyderS, et al.Evaluation of the biodistribution of 11C-methionine in children and young adults. J Nucl Med2013; 54: 1902–1908.
